Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 955 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Indications for Daratumumab June 10, 2021 Mom Thinks Baby Died Until Firefighters Say The Family Dog Made... June 4, 2019 Breast Cancer Survivor Comes First Woman In The World To Give... June 17, 2020 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 Load more HOT NEWS Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. Dad With Cancer Escorts His Autistic Son To School, With The... Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer...
